GLP-1 Antibody (ID/GLP-1/18): sc-73508
- GLP-1 Antibody (ID/GLP-1/18) is a mouse monoclonal IgG1, cited in 3 publications, provided at 100 µg/ml
- raised against a synthetic peptide corresponding to amino acids 7-36 of GLP-1 of human origin
- recommended for detection of GLP-1 (7-36) amide and GLP-1 (1-30) amide of human origin by IF and IHC(P); non cross-reactive with GLP-2, GRPP, PYY, VIP, PHI, GIP, Glucagon, or Oxyntomodulin
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for GLP-1 Antibody (ID/GLP-1/18). This work is in progress.
GLP-1 Antibody (ID/GLP-1/18) is a mouse monoclonal IgG1 antibody that detects glucagon-like peptide-1 (GLP-1) in human samples through immunofluorescence (IF) and immunohistochemistry with paraffin-embedded sections (IHCP). GLP-1 plays a crucial role in glucose metabolism and appetite regulation, functioning as a key incretin hormone that enhances insulin secretion in response to meals while simultaneously inhibiting glucagon release, thereby lowering blood sugar levels. GLP-1 is primarily produced in the intestinal L-cells and is vital for maintaining glucose homeostasis, making GLP-1 an important target for diabetes research and therapeutic interventions. Additionally, GLP-1 is known to promote satiety and reduce food intake, which is significant for obesity management. The interaction of GLP-1 with GLP-1R initiates a cascade of intracellular signaling pathways that not only influence insulin secretion but also enhance beta-cell proliferation and survival, highlighting GLP-1′s potential in regenerative medicine. Anti-GLP-1 antibody (ID/GLP-1/18) is an essential tool for researchers investigating the physiological and pathological roles of GLP-1 in human health.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
GLP-1 Antibody (ID/GLP-1/18) References:
- GLP-1 for type 2 diabetes. | Ahrén, B. 2011. Exp Cell Res. 317: 1239-45. PMID: 21237153
- Regulation of glucose homeostasis by GLP-1. | Nadkarni, P., et al. 2014. Prog Mol Biol Transl Sci. 121: 23-65. PMID: 24373234
- The incretin hormone GLP-1 and mechanisms underlying its secretion. | Tian, L. and Jin, T. 2016. J Diabetes. 8: 753-765. PMID: 27287542
- Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies. | Li, J., et al. 2017. Front Physiol. 8: 15. PMID: 28194113
- GLP-1 acts on habenular avoidance circuits to control nicotine intake. | Tuesta, LM., et al. 2017. Nat Neurosci. 20: 708-716. PMID: 28368384
- Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD. | Seghieri, M., et al. 2018. Front Endocrinol (Lausanne). 9: 649. PMID: 30459715
- Circulating GLP-1 Levels in Patients with Pheochromocytoma/Paraganglioma. | Chen, N., et al. 2022. Int J Endocrinol. 2022: 4203018. PMID: 36569401
- The alleviating effect and mechanism of GLP-1 on ulcerative colitis. | Wang, W., et al. 2023. Aging (Albany NY). 15: 8044-8060. PMID: 37595257
- A sympathetic brake on gut GLP-1 release. | López-Gambero, AJ., et al. 2024. Neuron. 112: 865-867. PMID: 38513615
- GLP-1: A Prospective Guardian for Comprehensive Myocardial Perfusion. | Li, Z., et al. 2024. Diabetes Metab Res Rev. 40: e70004. PMID: 39520208
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GLP-1 Antibody (ID/GLP-1/18) | sc-73508 | 100 µg/ml | $322.00 |